The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review

Dermatol Ther. 2020 May;33(3):e13456. doi: 10.1111/dth.13456. Epub 2020 May 3.

Authors

Trinidad Montero-Vilchez¹, Antonio Martinez-Lopez^{1

2}, Luis Salvador-Rodriguez¹, Salvador Arias-Santiago^{1

2

3}, Alejandro Molina-Leyva^{1

2

4}

Affiliations

¹ Hidradenitis Suppurativa Clinic, Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
² Instituto de Investigación Biosanitaria IBS, Granada, Spain.
³ Dermatology Department, University of Granada, Granada, Spain.
⁴ European Hidradenitis Suppurativa Foundation (EHSF), Dessau-Roßlau, Germany.

PMID: 32319172
DOI: 10.1111/dth.13456

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized
Hidradenitis Suppurativa* / diagnosis
Hidradenitis Suppurativa* / drug therapy
Humans

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
guselkumab